drugset
drugset / Trial / NCT02606903

Pharmacokinetics and Safety of BI 695501 Administered Via Prefilled Syringe or Autoinjector

NCT02606903 ↗

Phase 1 Completed 71 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-labelTreatment

Summary

To investigate and compare the pharmacokinetics, safety and tolerability of BI 695501 administered subcutaneously via prefilled syringe or autoinjector

Timeline

Start
2015-10-28
Primary completion
2016-09-07
Completion
2016-10-04

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 695501 Monoclonal antibody — Subcutaneous

Indications

No indication recorded.